

**Ref: 73/SE/LC/2025-26**

**Date: January 27, 2026**

Scrip Code BSE: 544122  
NSE: ENTERO  
ISIN: INE010601016

To,  
**Head, Listing Compliance Department**  
**BSE Limited**  
Phiroze Jeejeebhoy Towers Dalal Street,  
Mumbai - 400 001.

**Head, Listing Compliance Department**  
**National Stock Exchange of India Limited**  
Exchange Plaza, Plot No. C/1. G Block,  
Bandra -Kurla Complex, Bandra (East),  
Mumbai- 400051

Dear Sir/Madam,

**Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject matter, we would like to inform that Senior Drugs Control Officer cum Licensing Authority, Karnal Zone, has temporarily suspended the drug license of Atreja Healthcare Solutions Private Limited ("Atreja"), a wholly owned subsidiary of the Company, for a period of three days from 30.01.2026 to 01.02.2026, as an administrative action for the contraventions of provisions of Drugs and Cosmetics Act, 1940 read with rule 64 and 65 (5) of Drugs and Cosmetics Rules, 1945, while conducting its business by Atreja.

The details required to be furnished in compliance with Regulation 30 read with Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024, as amended, are enclosed as **Annexure-1**.

This is for your information and records.

Yours Faithfully  
For **Enter Healthcare Solutions Limited**

Sanu Kapoor  
**Vice President- General Counsel, Company Secretary**  
**& Compliance Officer**

**Annexure-1**

Details in terms of Regulation 30 read with Para A of Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024:

<b>Sr. No.</b>	<b>Particulars</b>	<b>Details</b>
I.	Name of the authority	Senior Drugs Control Officer cum Licensing Authority, Karnal Zone
II.	Nature and details of the action(s) taken or order(s) passed;	Temporary suspension of drug licenses of Atreja Healthcare Solutions Private Limited ("Atreja"), a wholly owned subsidiary of the Company for a period of three days from 30.01.2026 to 01.02.2026
III.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority;	27.01.2026
IV.	Details of the violation(s)/contravention(s) committed or alleged to be committed;	Violation of provisions of Drugs and Cosmetics Act, 1940 read with rule 64 and 65 (5) of Drugs and Cosmetics Rules, 1945
V.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	<p>There is no material impact on the financial, operations or other activities of Entero Healthcare Solutions Limited ("Entero") being a listed entity.</p> <p>Potential Revenue Loss of Rs~1.88 million.</p>